Table 1 The general information of the included studies
Study | Language | Publication form | Number of documents (case number) | Intervention measures (control vs treatment) | Outcomes | AMSTAR2 (point) | PRIMSA (point) |
|---|---|---|---|---|---|---|---|
Xu 2008 [20] | English | Journal | 10 (1185) | SIN vs single NSAIDs; SIN vs combined NSAIDs | (1) NIP; (2) NRP; (3) MS; (4) PJ; (5) SJ; (6) GS; (7) ESR; (8) CPR; (9) JTS; (10) AI | 6 | 17 |
Qi 2010 [30] | Chinese | Journal | 3 (280) | ZQFTN vs MTX; | (1) MS; (2) SJ; (3) PJ; (4) ESR; (5) RF; | 4 | 16 |
Zhang 2012 [31] | Chinese | Journal | 10 (1365) | NSAIDs + MTX + ZQFTN vs NSAIDs + MTX; MTX + ZQFTN vs MTX; NSAIDs + MTX + PED + ZQFTN vs NSAIDs + MTX + PED; MTX + SSZ + ZQFTN vs MTX + SSZ; LEF + MTX + ZQFTN vs LEF + MTX; | (1) ACR; (2) PJ; (3) SJ; (4) ESR; (5) CPR; (6) RF; | 7 | 17.5 |
Li 2012 [32] | Chinese | Journal | 8 (735) | ZQFTN + MTX vs MTX | (1) Total Effect; (2) MS; (3) ESR; (4) RF; (5) CRP; (6) Adverse Effects | 5 | 15.5 |
Wang 2015 [33] | Chinese | Journal | 6 (476) | ZQFTN + NSAIDs + MTX vs NSAIDs + MTX; ZQFTN vs OXA; ZQFTN + SSZ vs MTX + SSZ; ZQFTN + MTX vs MTX; ZQFTN + MTX vs MTX + D-Pen; ZQFTN + NSAIDS + MTX vs NSAIDs + MTX; | (1) Total Effect; (2) Adverse Effects; (3) MS; (4) ESR; (5) CPR; (6) RF; | 8 | 19 |
Chen 2015 [34] | English | Journal | 11 (956) | ZQFTN+MTX vs MTX; | (1) RF; (2) CPR; (3) ESR; (4) SJ; (5) MS | 6 | 16 |
Li 2016 [35] | Chinese | Journal | 8 (708) | NSAIDS + ZQFTN + MTX vs NSAIDs + MTX; ZQFTN + SSZ vs MTX + SSZ; ZQFTN + MTX vs MTX; ZQFTN + MTX vs MTX + D-Pen; ZQFTN + LEF + NSAIDS vs LEF + NSAIDs | (1) Total Effect; (2) Adverse Effects; (3) MS; (4) PJ; (5) GS; (6) SJ; (7) ESR; (8) RF; (9) CPR; | 7 | 20.5 |
Liu 2016 [21] | English | Journal | 16 (1500) | ZQFTN vs MTX; ZQFTN + MTX vs MTX; Basic therapy + ZQFTN + MTX vs Basic therapy + MTX | (1) Clinical efficacy; (2) MS; (3) Total clinical effective rate in 4 weeks treatment; (4) SJ; (5) GS; (6) ESR; (7) CPR; (8) Blood platelet; (9) DAS28; | 10 | 20 |